XOMA (NASDAQ:XOMA) Price Target Lowered to $104.00 at HC Wainwright

XOMA (NASDAQ:XOMA - Free Report) had its target price decreased by HC Wainwright from $123.00 to $104.00 in a research report sent to investors on Monday,Benzinga reports. HC Wainwright currently has a buy rating on the biotechnology company's stock.

Separately, StockNews.com upgraded shares of XOMA from a "sell" rating to a "hold" rating in a research report on Thursday, January 16th.

XOMA Stock Performance

XOMA stock traded down $0.23 during midday trading on Monday, hitting $26.11. 12,474 shares of the stock traded hands, compared to its average volume of 56,449. The firm has a market cap of $307.58 million, a P/E ratio of -7.50 and a beta of 0.90. The company has a debt-to-equity ratio of 1.28, a current ratio of 7.52 and a quick ratio of 7.52. The stock's fifty day simple moving average is $27.28 and its 200-day simple moving average is $28.03. XOMA has a 1-year low of $19.50 and a 1-year high of $35.00.

XOMA (NASDAQ:XOMA - Get Free Report) last released its quarterly earnings results on Thursday, November 7th. The biotechnology company reported ($0.39) EPS for the quarter, beating the consensus estimate of ($0.44) by $0.05. The company had revenue of $7.20 million for the quarter, compared to analyst estimates of $6.66 million. XOMA had a negative net margin of 151.34% and a negative return on equity of 24.95%. On average, analysts expect that XOMA will post -1.41 earnings per share for the current year.

Insider Buying and Selling at XOMA

In other XOMA news, major shareholder Bvf Partners L. P/Il sold 500,742 shares of the stock in a transaction on Friday, January 24th. The shares were sold at an average price of $26.10, for a total transaction of $13,069,366.20. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Owen Hughes sold 21,881 shares of the stock in a transaction on Wednesday, November 13th. The shares were sold at an average price of $29.95, for a total transaction of $655,335.95. Following the transaction, the chief executive officer now directly owns 34,979 shares in the company, valued at approximately $1,047,621.05. The trade was a 38.48 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 7.20% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. BNP Paribas Financial Markets increased its holdings in shares of XOMA by 95.0% in the third quarter. BNP Paribas Financial Markets now owns 1,632 shares of the biotechnology company's stock valued at $43,000 after purchasing an additional 795 shares during the last quarter. New York State Common Retirement Fund lifted its position in XOMA by 51.2% during the fourth quarter. New York State Common Retirement Fund now owns 2,362 shares of the biotechnology company's stock worth $62,000 after buying an additional 800 shares in the last quarter. Los Angeles Capital Management LLC purchased a new position in XOMA during the fourth quarter worth approximately $206,000. Rhumbline Advisers lifted its position in XOMA by 18.1% during the fourth quarter. Rhumbline Advisers now owns 11,065 shares of the biotechnology company's stock worth $291,000 after buying an additional 1,699 shares in the last quarter. Finally, Barclays PLC lifted its position in XOMA by 300.7% during the third quarter. Barclays PLC now owns 11,256 shares of the biotechnology company's stock worth $298,000 after buying an additional 8,447 shares in the last quarter. 95.92% of the stock is owned by hedge funds and other institutional investors.

XOMA Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.